These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7850293)

  • 21. [External radiotherapy with curative intent for adenocarcinoma clinically localized to the prostate (T1 to T3N0M0): intermediate results with a minimum follow-up of 4 years].
    Rohner S; Bieri S; Graber P
    Ann Urol (Paris); 1994; 28(4):221-8. PubMed ID: 7979212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant radiotherapy in patients with pathologic Stage C (pT3N0) adenocarcinoma of the prostate.
    Petrovich Z; Lieskovsky G; Langholz B; Bochner B; Formenti S; Streeter O; Skinner DG
    Urology; 1999 Jun; 53(6):1184-93. PubMed ID: 10367850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Moderate hypofractionated external beam radiotherapy alone for intermediate risk prostate cancer: long term outcomes.
    Faria SL; Neto OB; Cury F; Shenouda G; Russel R; Souhami L
    Can J Urol; 2016 Apr; 23(2):8209-14. PubMed ID: 27085825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors.
    Brooks JP; Albert PS; Wilder RB; Gant DA; McLeod DG; Poggi MM
    J Urol; 2005 Dec; 174(6):2204-8, discussion 2208. PubMed ID: 16280764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy.
    Fosså A; Lilleby W; Fosså SD; Gaudernack G; Torlakovic G; Berner A
    Int J Cancer; 2002 May; 99(1):100-5. PubMed ID: 11948499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
    Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
    BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose radiotherapy for localized prostatic cancer. An analysis of treatment results and early complications.
    Kearsley JH
    Med J Aust; 1986 Jun; 144(12):624-8. PubMed ID: 3086680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.
    Gutt R; Tonlaar N; Kunnavakkam R; Karrison T; Weichselbaum RR; Liauw SL
    J Clin Oncol; 2010 Jun; 28(16):2653-9. PubMed ID: 20421534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy.
    Tsien C; Griffith KA; Sandler HM; McLaughlin P; Sanda MG; Montie J; Reddy S; Hayman JA
    Urology; 2003 Jul; 62(1):93-8. PubMed ID: 12837430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer.
    Zelefsky MJ; Whitmore WF
    J Urol; 1997 Jul; 158(1):23-9; discussion 29-30. PubMed ID: 9186315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer.
    Robnett TJ; Whittington R; Malkowicz SB; Brereton HD; Van Arsdalen K; Drach G; Wein AJ
    Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1146-51. PubMed ID: 12128114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years.
    Anscher MS; Clough R; Dodge R
    Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):369-75. PubMed ID: 10974449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy.
    Green GA; Hanlon AL; Al-Saleem T; Hanks GE
    Cancer; 1998 Sep; 83(5):971-6. PubMed ID: 9731902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome.
    Zagars GK; Pollack A
    Urology; 1995 Mar; 45(3):476-83. PubMed ID: 7533459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
    Choo R; Hruby G; Hong J; Hong E; DeBoer G; Danjoux C; Morton G; Klotz L; Bhak E; Flavin A
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):674-80. PubMed ID: 11849789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiotherapy for regionally localized hormone refractory prostate cancer.
    Lankford SP; Pollack A; Zagars GK
    Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):907-12. PubMed ID: 7591901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.